Senseonics Launches First Freedom Glucose Monitor Study

The investigational implantable sensor aims to monitor blood glucose levels for up to one year.

Updated on Oct. 28, 2026 in Diabetes

Gouache-painted illustration of a small, minimalist titanium sensor, representing long-term medical monitoring technology. — Senseonics has begun the first clinical study of its Freedom glucose monitor, an implantable device designed for year-long blood sugar tracking. AI Illustration. Upload story photo >

Live Poll

Would you trust a medical monitor that lacks an external device for alerts and data storage?

Senseonics has initiated its first human clinical study of the Freedom glucose monitor, a device designed for long-term blood sugar tracking. The technology integrates both battery and Bluetooth components directly into an implantable sensor.

Why it matters

The design seeks to improve patient convenience by eliminating the need for daily adhesive changes and external transmitters. If successful, it would represent a significant shift in long-term diabetes management.

The Freedom system is engineered to function for a full 365 days following a single insertion procedure. Preclinical trials successfully validated the hardware performance with 18,500 data points collected.

The players

Senseonics

Senseonics is a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems.

The details

Freedom allows glucose readings to transmit directly to a smartphone without an external transmitter, requiring a surgical procedure for initial placement and annual replacement. This approach is intended to streamline the monitoring process for individuals managing diabetes.

Preclinical testing was completed in the second quarter of 2026.
The first human study of the Freedom system began on October 26, 2026.
A larger pivotal trial is scheduled for 2027.
The company targets a potential commercial launch in 2028.

Health Landscape

The Freedom device represents a further evolution of the Eversense continuous glucose monitoring system by removing the need for an external transmitter. This study advances the capability of current implantable monitors by integrating wireless communication directly into the sensor.

If the device receives future regulatory approval, patients could eventually transition away from daily adhesive changes and the reliance on rechargeable external transmitters. This would provide a more discreet and low-maintenance option for continuous blood sugar tracking.

The takeaway

The development of a self-contained implantable monitor highlights a broader industry trend toward reducing the daily burden of medical device maintenance. Patients should monitor official company updates as the technology moves through the planned 2027 clinical trials.